Currently, sonidegib and vismodegib are two systemic SMO antagonists, with sonidegib approved for adult patients with laBCC and vismodegib approved for adult patients with laBCC or mBCC [2]. In this case, vismodegib was successful in reducing the size of the patient’s large BCC and resulted in the complete regression of smaller lesions on his upper extremities. This evidence concerns the gene SMO and skin basal cell carcinoma.